Marlodon

Methadone, the active ingredient in Marlodon, is an opioid agonist presented as an oral formulation for oral use. It treats opioid dependence and chronic pain in adults.

GNH USA supplies Marlodon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marlodon (methadone) acts on the opioid system to manage dependence and pain.

- Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe, persistent pain. - Opioid detoxification: facilitates a controlled transition from illicit opioids to abstinence.

Marlodon may cause a range of adverse reactions.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: mild to moderate upset stomach. - Drowsiness: increased sedation, especially after dose initiation. - Sweating: excessive perspiration, often during dose adjustments.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.

Marlodon requires careful monitoring due to its potency and pharmacologic profile.

- Assess liver function: adjust dosing in hepatic impairment. - Monitor cardiac conduction: baseline ECG and periodic QT interval checks. - Avoid in acute respiratory insufficiency: risk of severe respiratory depression. - Use caution in pregnancy: potential neonatal withdrawal syndrome. - Store at below 25°C: keep in the original pack, protect from moisture.

Marlodon can interact with several medication classes, necessitating vigilance.

Major Interactions (Avoid): - CNS depressants: additive sedation and respiratory depression. - QT‑prolonging agents: increased risk of cardiac arrhythmias. - MAO inhibitors: risk of severe hypotension and serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise methadone plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce methadone effectiveness.